ArticleDiscovery medicine2014
Understanding autoimmunity in the eye: from animal models to novel therapies.
Article in Discovery medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Neopterin Levels and Immune Response in Autoimmune Uveitis in an Experiment.Korean journal of ophthalmology : KJO · 2025Article
- Corneal application of SOCS1/3 peptides for the treatment of eye diseases mediated by inflammation and oxidative stress.Frontiers in immunology · 2024Review
- microRNA 146a ameliorates retinal damage in experimental autoimmune uveitis.Frontiers in ophthalmology · 2023Article
- Blood-retina barrier dysfunction in experimental autoimmune uveitis: the pathogenesis and therapeutic targets.Anatomy & cell biology · 2022Review
- Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis.Journal of visualized experiments : JoVE · 2021Article
- Association between uveitis and psoriatic disease: a systematic review and Meta-analysis based on the evidence from cohort studies.International journal of ophthalmology · 2020Article
- Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Psoriasis and uveitis: links and risks.Psoriasis (Auckland, N.Z.) · 2019Article
- Cytokines in uveitis.Current opinion in ophthalmology · 2018Review
- Negative regulators that mediate ocular immune privilege.Journal of leukocyte biology · 2018Review
- A systems approach to renal inflammation in SLE.Clinical immunology (Orlando, Fla.) · 2017Review
- Advancements in Understanding Immunogenicity of Biotherapeutics in the Intraocular Space.The AAPS journal · 2017Review
- Comprehensive analysis of mouse retinal mononuclear phagocytes.Nature protocols · 2017Article
- Autoimmune uveitis: clinical, pathogenetic, and therapeutic features.Clinical and experimental medicine · 2016Review
- Drug discovery in ophthalmology: past success, present challenges, and future opportunities.BMC ophthalmology · 2016Review
- IL-27-induced modulation of autoimmunity and its therapeutic potential.Autoimmunity reviews · 2015Review
- Mesenchymal stem cells in the treatment of inflammatory and autoimmune diseases in experimental animal models.World journal of stem cells · 2015Review
- Experimental autoimmune uveitis and other animal models of uveitis: An update.Indian journal of ophthalmology · 2015Review
- Retinal antigen-specific regulatory T cells protect against spontaneous and induced autoimmunity and require local dendritic cells.Journal of neuroinflammation · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
In recent years considerable headway has been made on understanding the mechanisms underlying inflammatory diseases of the eye. This includes the role of the innate vs. adaptive arms of the immune systems in disease, the concept that distinct immune pathways can drive end-organ pathology, and the role as well as limitations of immune privilege in controlling the innate and adaptive effector responses that lead to eye pathology and loss of vision. These insights have largely been derived from basic studies in established and in newly developed animal models of uveitis. The increased understanding of disease mechanisms has the potential to guide development of rational therapies for human uveitis. Many novel biologics currently in use or being evaluated have been developed, or validated, in animal models of autoimmune and inflammatory disease, including experimental uveitis. Paradoxically, and fueled in part by dwindling research budgets, a campaign has been gathering momentum against use of animal models in preclinical research, as being poorly representative of responses in humans. Given the extensive genetic similarity between humans and laboratory rodents as revealed by the Human, Mouse and Rat Genome Projects, and the finding that almost all known disease-associated genes have orthologs in mice and rats, perhaps the problem is our still-insufficient understanding of mechanisms and inadequate knowledge of species differences, resulting in poor choice of models, rather than in an inherent unsuitability of animal models to represent human disease.
Indexed as
Identifiers
24641958PMC4573559What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.